1588
The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
 ( adverse event: development ,  a patient with rheumatoid arthritis.: Subject, systemic lupus erythematosus: Effect, after 38 months: Treatment, recombinant human interferon gamma: Treatment, after 38 months: Treatment.Time_elapsed, recombinant human interferon gamma: Treatment.Drug, rheumatoid arthritis.: Treatment.Disorder) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: development ,  a patient with rheumatoid arthritis.: Subject, systemic lupus erythematosus: Effect, after 38 months: Treatment, recombinant human interferon gamma: Treatment, after 38 months: Treatment.Time_elapsed, recombinant human interferon gamma: Treatment.Drug, rheumatoid arthritis.: Treatment.Disorder) 